Methods | We obtained data from the Ontario Health Insurance Plan (OHIP), Ontario Drug Benefit (ODB) Database, Discharge Abstract Database (DAD), and the National Ambulatory Care Reporting System (NACRS). We used intercensal and postcensal projections based on census data from 2001, 2006, and 2011 to estimate the Ontario population. The OHIP physician billing database captures approximately 98% of all physician billings for the province of Ontario and includes diagnosis and procedure codes. The ODB database identifies prescription claims for medications covered under the provincial drug formulary for individuals aged older than 65 years. The DAD and NACRS databases contain diagnosis and procedure information for all hospital admissions and emergency department visits in Ontario. By law in Ontario, all hospital and emergency department admissions are included in these databases, so the sampling frame is population-based.
This prospective longitudinal population-based study was approved by the Sunnybrook Health Sciences Centre Research Ethics Board. Patient consent was waived because data collection for the registry is done without patient consent, as the Institute for Clinical Evaluative Sciences is named as a prescribed entity under provincial privacy legislation.
We identified strokes in DAD and NACRS using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes I60, I61, I63, and I64 and OHIP codes 430, 431, 434, and 436 . We defined acute stroke as 1 hospitalization (DAD) or 1 emergency department visit (NACRS) with a most responsible diagnosis of stroke, or 2 OHIP claims for physician visits with a diagnosis of stroke within the 365- We included patients aged 20 years or older, diagnosed as having stroke between April 1, 2002, and March 31, 2014. We excluded patients with invalid health card numbers, missing age/sex, and nonresidents of Ontario. We established a lookback window of 7 years (1995) (1996) (1997) (1998) (1999) (2000) (2001) to exclude cases diagnosed before the study period. As a result, any case identified between April 1, 1995, and March 31, 2002, was not counted, and for each given fiscal year, the individuals with prevalent dementia were also removed from the denominator. Cases with multiple strokes or multiple dementia codes over the study period contributed only once. We calculated stroke and dementia age-and sex-standardized incident rates per 1000 inhabitants for each fiscal year between 2002 and 2013 (12 years).
Results | Between 2002 and 2013, age-and sex-standardized stroke and dementia incidence rates in the Ontario population decreased by 32.4% (P < .001) and 7.4% (P = .009), respectively (Table and Figure) .
Discussion | To our knowledge, this is the first study showing a decline in dementia incidence over time. This report may also be unique in showing a corresponding decline in stroke incidence in the same population. Previous evidence suggests that diet, exercise, cognitive training, and vascular risk monitoring may improve or maintain cognitive functioning in at-risk elderly people. 4 Hence, primary prevention strategies resulting in improved risk-factor control may have concurrently reduced dementia risk. 5 In addition, given that cerebrovascular disease is an important cause of dementia and that 60 to 80% of all major dementias have a vascular component, the falling incidence of stroke may have further contributed to the decline in dementia incidence. P value for trend in stroke incidence <.001 P value for trend in dementia incidence = .009 (Jonckheere-Terpstra Test)
Dementia Stroke
The error bars represent 95% CIs.
Letters

Long-term Safety and Efficacy of Mexiletine for Patients With Skeletal Muscle Channelopathies
The skeletal muscle channelopathies include the nondystrophic myotonias and the periodic paralyses. Myotonia is the core clinical feature of the nondystrophic myotonias and may be a feature of hyperkalemic periodic paralysis. It is caused by mutations in the skeletal muscle voltage-gated chloride channel gene CLCN1 or sodium channel gene SCN4A. Adequate treatment of myotonia is important for quality of life, mobility, and functional independence.
1 Mexiletine acts on voltage-gated sodium channels. Its most frequent adverse effect is gastrointestinal 2,3 but minor neurological effects (eg, tremor) are also reported. 4, 5 Two randomized clinical trials have demonstrated the efficacy of mexiletine for the short-term treatment of myotonia 2,3 but long-term safety and efficacy data outside a trial setting are lacking. We performed a retrospective review of our large skeletal muscle channelopathy patient cohort to address this.
Methods | All patients with genetically confirmed nondystrophic myotonia or hyperkalemic periodic paralysis prescribed mexiletine with a minimum of 6 months follow-up in our clinic were included. Study data were collected as part of a clinical audit registered with the hospital audit committee. This study received ethical approval from the National Hospital for Neurology and Neurosurgery and Institute of Neurology Joint Research Ethics committee. Because data were collected as part of a clinical audit, such evaluations do not require patient consent. The standard dose titration was increments of 50 to 100 mg of mexiletine per week until symptoms resolved or a total daily dose of 600 mg was reached. Efficacy was determined by patient report. Any symptom or adverse event not clearly attributable to an alternative cause was included. All available electrocardiograms (ECGs) were reexamined. Heart rate, PR interval (P wave to beginning of QRS complex), QRS duration (Q wave to end of S wave), and corrected QT interval (QTc) were noted or calculated manually. The corrected QT interval was calculated using Medcalc (http://www.medcalc.com/qtc .html). Significance was assessed using paired t test or 1-way analysis of variance then unpaired t test.
Results | A total of 122 patients were identified; 63 met inclusion criteria. Forty patients had mutations in CLCN1, 21 in SCN4A, and 2 in both CLCN1 and SCN4A (subsequently analyzed with the SCN4A group). The mean length of follow-up was 4.8 years (range, 6 months to 17.8 years).
There were no serious adverse events. Paired assessment of ECG parameters while not taking mexiletine and at the highest dose at which an ECG was recorded for each individual revealed no significant change in heart rate (71 beats per minute vs 71 beats per minute; P = .97), PR interval (154 
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A, Any symptom or adverse event reported while taking mexiletine was included unless there was a clear alternative precipitant. Because some patients reported more than 1 adverse event, the total exceeds 100%. B, Distribution of adverse events by genotype. Because some patients reported more than 1 adverse event, in some cases, the total exceeds the total number of patients in that category. CLCN1 missense indicates all patients with CLCN1 missense mutations only (dominant or recessive myotonia congenita); heterozygous (Het) NMD, patients with recessive myotonia congenita with 1 CLCN1 missense mutation and 1 CLCN1 mutation associated with nonsense mediated decay; homozygous (Hom) NMD, patients with recessive myotonia congenita with 2 mutations associated with nonsense mediated decay; and SCN4A missense, all patients with SCN4A mutations. a Other adverse effects were breathlessness (3.1%), vivid dreams (1.5%), tremor and dizziness (1.5%), loose stool, change in ejaculate and fatigue (1.5%), blepharospasm, and the inability to focus (1.5%). 
